Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

T2 Biosystems Continues To Expect FY24 Total Sepsis Product Revenue Of $10M - $11M, Representing Growth Of 49% To 64% Y/Y

Author: Benzinga Newsdesk | July 29, 2024 04:39pm

Posted In: TTOO